Aptorum Group Limited and DiamiR Biosciences Corp. announced on July 16, 2025, that they have entered into a definitive agreement for an all-stock merger transaction. Under this agreement, DiamiR Biosciences will become a wholly-owned subsidiary of Aptorum Group upon the consummation of the merger.
The combined company expects to maintain its listing on the Nasdaq Stock Market following the closing of the merger. DiamiR shareholders are anticipated to own approximately 70% of the outstanding common stock of the combined entity, with existing Aptorum shareholders retaining 30%.
This strategic move is expected to create a more comprehensive and diversified biopharmaceutical company, leveraging DiamiR's expertise in blood-based diagnostics for brain health. The merger is projected to deliver near and long-term value through revenue generation from biopharma services and biomarker panels for complex-biology indications, while establishing leadership in non-invasive, blood-based testing. The proposed merger is expected to close in the fourth quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.